CCTA Shows How Even Mild Plaque Boosts Cardiac Risk

<strong>AuntMinnie | </strong>Asymptomatic adults with a low Framingham risk score (FRS) and nonsignificant
coronary artery disease still face a higher risk of death and adverse events if
mild coronary artery plaque is present at coronary CT angiography (CCTA),
according to a study from Cedars-Sinai Medical Center in Los Angeles presented
at the 2011 American College of Cardiology (ACC) meeting.

In more than 18,000 asymptomatic individuals with nonobstructive coronary
artery stenosis less than 50%, the risk of death and cardiac events was far
higher than in patients who tested negative at CCTA, the investigators said.

The focus on nonobstructive plaque is new territory for CCTA, lead researcher
Dr. James Min told AuntMinnie.com. Until recently, evaluating the
accuracy of coronary CTA has been limited to the detection and exclusion of
obstructive coronary artery disease (CAD). But recent studies have highlighted
the ability of CCTA to identify mild forms of atherosclerosis, as compared to
intravascular ultrasound.

In addition, autopsy studies have implicated nonobstructive CAD as central to
the pathophysiologic processes of sudden cardiac death and myocardial
infarction, he said. Still, whether CCTA plaque assessment in individuals
without obstructive CAD enhances risk prediction has not been well examined, Min
said.

Therefore, the study aimed to examine the predictive value of nonobstructive
CAD extent and severity as detected by CCTA for intermediate-term mortality risk
among patients referred for suspected CAD, Min said. Study data were compiled
from the Coronary CT Angiography Evaluation for Clinical Outcomes: An
International Multicenter Registry (CONFIRM) results. CONFIRM enrolled 27,125
consecutive adults 18 years or older, who received CCTA exams for suspected CAD
on scanners with 64 detector rows or more at Cedars-Sinai and 12 other centers
in the U.S. and Europe.

The researchers prospectively gathered data on risk factors for heart
disease, including hypertension, diabetes, dyslipidemia, smoking status and
history, and family history of CAD.

Coronary CTA scans were performed on a variety of CT scanners including
LightSpeed VCT (GE
Healthcare
), Somatom Definition (Siemens
Healthcare
), and Somatom Definition Flash. Parameters included 64 x 0.625 or
0.750-mm collimation, 100- or 120-mV tube voltage, and effective 400 mA to 650
mA. Dose reduction techniques included electrocardiogram (ECG)-gated tube
current modulation, reduced tube voltage, and prospective axial triggering
employed wherever feasible. Total estimated radiation dose for CCTA ranged from
3 mSv to 18 mSv.

All scans were read by highly experienced cardiologists, who scored the
images for the presence of plaque using a 16-segment coronary artery model.
Stenosis severity was scored as none (0% luminal stenosis), mild (1% to 49%
luminal stenosis), moderate (50% to 69% luminal stenosis), or severe (≥ 70%
luminal stenosis), Min said.

Plaque severity was graded per-patient, per-vessel, and per-segment, based on
the maximum severity in any segment:

  • For U.S. patients, the team examined death by all causes, verified by the
    Social Security Death Index.
  • For both U.S. and non-U.S. sites, death or myocardial infarction was
    verified by clinical visits, telephone contacts, and questionnaires sent by
    mail. Verification of all reported events was taken from hospital records or
    from direct contact with a patient’s attending physician.
  • Events occurring less than 90 days after the index test were excluded from
    analysis.

Patients with either moderate or severe stenosis were also excluded from the
analysis, leaving 18,037 patients with stenosis of 50% or less in the cohort
that was followed for 2.3 years (± 1.1), according to Min.

Nonobstructive CAD hazards ratio
The above chart shows numerical values for
increasing risks of cardiac events in the presence of one or more coronary
artery vessels; a graphic representation of similar data is shown below. All
images courtesy of Dr. James Min.
Increasing hazards for increasing numbers of segments

 

Hazards with low FRS and no modifiable risk factors
The risk of adverse events for patients with
nonobstructive coronary artery disease remains elevated even for patients with a
low Framingham risk score and no modifiable risk factors.

 

Kaplan-Meier curves
Unadjusted Kaplan-Meier curve shows decreasing
survival over 2.3 years for each additional vessel with nonobstructive coronary
artery plaque.

 

“In a large, prospective, multicenter CONFIRM registry, the absolute presence
and extent of nonobstructive CAD by CCTA is predictive of incident adverse
events, including death and nonfatal myocardial infarction,” Min said. “The
prognostic value of CCTA findings in patients with nonobstructive CAD applies
even to patients with low FRS and patients with no medically modifiable CAD risk
factors.”

On the other hand, the absence of CAD by CCTA is associated with a very
favorable prognosis — just 0.27% events yearly, he said.

CCTA as a gatekeeper may permit a reduction in “unnecessary, unhelpful, and
unsafe diagnostic invasive angiography … and uncouple the
diagnostic-therapeutic cascade,” Min said.

Future studies examining the treatment of patients with nonobstructive CAD by
CCTA are necessary to refine treatment protocols for these patients, he added.

Kyle Henneberry, M.D.

Associate Chief Medical Officer
Dr. Kyle Henneberry is a radiologist, health-tech innovator and one of the founders and principals of Direct Radiology. A native of Spokane, Washington, he graduated with honors in Biomedical Engineering from Northwestern University, received his medical degree from Case Western Reserve University in Cleveland, Ohio, and completed radiology residency at the University of Colorado. Dr. Henneberry has United States, Europe, Australia, and New Zealand.

Jerry Lee

Chief Technology Officer

Jerry Lee has over 25 years of experience in healthcare IT. and has been with ONRAD since 2013. As the CTO, he is responsible for developing the organization’s technology strategy including IT infrastructure, application development, data analytics, cybersecurity and overall risk management. Lee’s focus is on strategic road mapping, leveraging emerging technologies and business intelligence to automate, streamline and optimize business processes. He previously worked as a senior healthcare IT consultant, where he implemented best practices, policies & procedures, and risk mitigation strategies for a variety of clients. He also previously worked as the Business Intelligence and Analytics Project Manager for a leading healthcare SaaS organization. He graduated with a B.S. from the University of California, Irvine.

Leandra Hutchinson

President, Direct Radiology

Leandra Hutchinson joined ONRAD alongside the acquisition of Direct Radiology in December 2024. Hutchison has broad experience in the healthcare industry, spending her career in healthcare technology and innovation. Prior to joining Direct Radiology in 2019, Leandra was the co-founder and Vice President of Operations of a health-tech company specializing in radiology analytics and healthcare asset management. Previously, Leandra worked in marketing, strategy, and operations roles for more than 10 years at a $7B integrated delivery system of hospitals and medical centers with more than 900 employed physicians. Hutchison earned her Bachelor’s degree from Kent State University and graduate certificate in health care policy and administration and MBA from the University of Toledo.

Ron Jackson

President, AllRads

Ron Jackson serves as President of AllRads at ONRAD, bringing over 30 years of comprehensive healthcare leadership across the provider, payer, and technology landscape. With deep expertise in radiology, he has spent more than 25 years in revenue cycle management, operations, finance, and practice management roles at leading organizations including HBOC, Per-Se Technologies, McKesson, and Zotec Partners. At ONRAD, Jackson leads day-to-day operations and strategic execution of AllRads, drawing on his cross-functional experience to drive efficiency, scalability, and growth. His 360-degree perspective of the healthcare ecosystem uniquely positions him to align organizational strategy with market dynamics in teleradiology and imaging services.

Alix Vincent, M.D.

Chief Medical Officer

Dr. Alix Vincent was one of the founding physicians at ONRAD. With over 26 years of radiology leadership experience, Dr. Vincent oversees medical staff activities, including patient safety, quality, and risk management initiatives. He manages ONRAD’s Regional Medical Directors, evaluates staff physicians, and drives clinical improvements to enhance physician alignment within the organization. Additionally, Dr. Vincent leads medical operations and played a key role in developing the company’s PACS and RIS Network capabilities. He previously served as Chief Radiologist and Chairman of the Radiology Department at Riverside Regional Medical Center. Dr. Vincent holds an M.D. in Radiology from Loma Linda University.

Lyn Mize

Chief Financial Officer

Lyn Mize serves as Chief Financial Officer at ONRAD, a role she has held since June 2022. With over two decades of experience in financial leadership, Mize has held CFO positions at various healthcare organizations, including Sunset Media Entertainment and Oncology Convergence, Inc. She also served as Vice President of Accounting at Health Choice and System Director of Accounting at Scottsdale Healthcare. Mize has a strong background in financial management, having worked with Banner Health and Greeley Medical Clinic, where she provided financial leadership for multi-specialty clinics and physician networks. Mize holds extensive expertise in driving financial performance and strategic growth across the healthcare sector and has a B.S. from DeVry University and a Masters from Grand Canyon University.

Dave Engert

President & CEO

Dave Engert started at Onrad as President and CEO in 2017. Engert is a seasoned healthcare executive with over 35 years of experience and a proven track record of leading and transforming healthcare technology organizations to drive growth and improve operational and financial performance. He previously served as President and CEO of Nighthawk Radiology, the largest teleradiology provider, and led its successful sale to vRad. Engert also held the role of President and CEO of Quality Care Solutions (QCSI), a leading provider of health insurance software, which was sold to Trizetto. Additionally, he has held leadership roles at McKesson, HBOC, and other notable companies and invested in several healthcare technology ventures. Engert holds a B.S. in Industrial Engineering from Louisiana State University.